Key statistics
On Monday, Alvotech SA (ALVO:NMQ) closed at 3.96, 4.76% above its 52-week low of 3.78, set on Mar 02, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 3.89 |
|---|---|
| High | 4.01 |
| Low | 3.78 |
| Bid | 3.71 |
| Offer | 4.02 |
| Previous close | 3.99 |
| Average volume | 797.93k |
|---|---|
| Shares outstanding | 311.72m |
| Free float | 117.87m |
| P/E (TTM) | 18.92 |
| Market cap | 1.23bn USD |
| EPS (TTM) | 0.2093 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- Transactions of Managers and Closely Associated Persons
- Viðskipti stjórnenda og tengdra aðila
- Alvotech tilkynnir um aukningu í fjölda eigin bréfa
- Alvotech Announces Increase in Number of Own Shares
- Alvotech kynnir jákvæða niðurstöðu rannsóknar á lyfjahvörfum AVT80, fyrirhugaðrar hliðstæðu við líftæknilyfið Entyvio
- Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
- Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
- Alvotech gerir samninga um markaðssetningu á fyrirhuguðum hliðstæðum í Kanada, Ástralíu og Nýja-Sjálandi
- Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
- Alvotech nær samningum um alþjóðlega markaðssetningu hliðstæðu við augnlyfið Eylea
More ▼
